Merck Reports P-III (CORALreef AddOn) Trial Data on Enlicitide Decanoate in Hypercholesterolemia

Why It Matters

The data suggest enlicitide could become the most potent oral non‑statin option, reshaping lipid‑lowering therapy and potentially reducing cardiovascular events.

Key Takeaways

• Enlicitide cut LDL‑C 64.6% in eight weeks.
• Outperformed bempedoic acid, ezetimibe, and their combo.
• ApoB dropped 54.6%, far exceeding comparators.
• Lp(a) reduced 26.2% versus modest increases elsewhere.
• 78% achieved LDL‑C <55 mg/dL with ≥50% reduction.

Pulse Analysis

The management of elevated low‑density lipoprotein cholesterol (LDL‑C) remains a cornerstone of cardiovascular risk reduction, yet many patients cannot achieve guideline targets with statins alone. Injectable PCSK9 antibodies have filled the efficacy gap, but their administration burden limits uptake. Merck’s enlicitide decanoate, an oral small‑molecule PCSK9 inhibitor, promises comparable potency with the convenience of a daily pill. If the Phase III CORALreef AddOn data hold up, clinicians could finally prescribe a truly oral, high‑intensity lipid‑lowering regimen without sacrificing efficacy.

The eight‑week interim analysis revealed a 64.6 % LDL‑C reduction, dwarfing the 56.7 % drop seen with bempedoic acid, the 36 % reduction from ezetimibe, and the 28.1 % from their combination. ApoB, a more precise marker of atherogenic particles, fell 54.6 % versus modest declines of 5‑20 % with comparators, while non‑HDL‑C and Lp(a) also improved markedly. Most strikingly, 78.2 % of participants achieved LDL‑C below 55 mg/dL with at least a 50 % reduction, a benchmark rarely met by oral agents, indicating a potential shift in therapeutic algorithms.

From a commercial perspective, enlicitide could challenge both injectable PCSK9 antibodies and existing oral non‑statins, expanding Merck’s cardiovascular portfolio and addressing an unmet market segment estimated at billions of dollars. Regulatory approval pathways may be accelerated given the magnitude of lipid lowering and the favorable safety profile reported at ACC 2026. Payers will likely favor an oral therapy that reduces the need for costly injections, while patients gain adherence benefits. Competitors will be forced to accelerate oral PCSK9 programs, intensifying innovation across the lipid‑lowering landscape.